You have 9 free searches left this month | for more free features.

Androgen Antagonists

Showing 1 - 25 of 1,601

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Prostate Cancer Trial in Atlanta, Charleston (Opaganib, Abiraterone, Enzalutamide)

Recruiting
  • Prostate Cancer
  • Atlanta, Georgia
  • +1 more
Dec 28, 2022

Prostate Cancer, Neoadjuvant Therapy, Androgen Antagonists Trial in Leuven (ARN-509, Degarelix, Placebo)

Recruiting
  • Prostate Cancer
  • +3 more
  • Leuven, Vlaams-brabant, Belgium
    University Hospitals Leuven
Dec 23, 2020

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Breast Cancer With or Without BRCA Mutation

Recruiting
  • Breast Cancer
  • Androgen receptor status and BRCA mutation
  • Varanasi, UP, India
    Banaras Hindu University
Jun 2, 2022

Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 Trial in Houston (drug, procedure,

Recruiting
  • Prostate Carcinoma
  • +6 more
  • Abiraterone Acetate
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of

Recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • 6-month course of antiandrogen drugs
  • Long-term course of antiandrogen drugs
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023

Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

Not yet recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
  • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 4, 2023

Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor

Not yet recruiting
  • Androgen Deprivation Therapy
  • +4 more
  • Gonadotropin-Releasing Hormone Agonist
  • +2 more
  • (no location specified)
Jan 18, 2023

Metastatic Malignant Tumor in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7 Trial in

Active, not recruiting
  • Metastatic Malignant Neoplasm in Lymph Node
  • +3 more
  • Antiandrogen Therapy
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 3, 2022

Prostate Cancer, Prostate Adenocarcinoma Trial (drug, other, procedure)

Not yet recruiting
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • (no location specified)
Feb 2, 2023

Prostatic Tumors Trial in Korea, Republic of (Leuprorelin, Goserelin, Triptorelin)

Recruiting
  • Prostatic Neoplasms
  • Cheongju, Korea, Republic of
  • +9 more
Jul 28, 2021

Transgender Women Trial in Pathum Wan (Estradiol, Estradiol and Anti-Androgen, No intervention)

Completed
  • Transgender Women
  • Estradiol
  • +2 more
  • Pathum Wan, Bangkok, Thailand
    Faculty of Sports Science, Chulalongkorn University
Nov 2, 2023

Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Prostate Carcinoma Trial in Seattle

Active, not recruiting
  • Castration-Sensitive Prostate Carcinoma
  • +7 more
  • Antiandrogen Therapy
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 8, 2022

Stage IV Prostate Adenocarcinoma AJCC v7 Trial in Worldwide (drug, other, procedure)

Recruiting
  • Stage IV Prostate Adenocarcinoma AJCC v7
  • Antiandrogen Therapy
  • +5 more
  • Duarte, California
  • +15 more
Jan 24, 2023

In-vitro Diagnostic Test to Predict COVID-19 Mortality and

Recruiting
  • SARS-CoV 2
  • +5 more
  • CAG length <22
  • CAG length >=22
  • Madrid, Spain
    Hospital Universitario Ramon y Cajal
Feb 17, 2022

Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8 Trial in Philadelphia

Recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • MRI-guided Intensity-Modulated Radiation Therapy
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 4, 2023

Prostate Cancer Trial in Worldwide (Degarelix, approved GnRH agonist, Radiotherapy)

Recruiting
  • Prostate Cancer
  • Brussels, Belgium
  • +38 more
Sep 3, 2021

Non-Muscle Invasive Bladder Cancer Trial in Québec (Bicalutamide, Control Arm)

Recruiting
  • Non-Muscle Invasive Bladder Cancer
  • Québec, Canada
    CHU de Québec-Université Laval
Jul 13, 2022

Prostatic Hyperplasia, Prostate Cancer Trial in Turku (Prostate hyperplasia medication, LhRH-antagonist)

Recruiting
  • Prostatic Hyperplasia
  • Prostate Cancer
  • Turku, Finland
  • +1 more
Aug 17, 2023

Prostatic Tumors Trial in Worldwide (Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT))

Active, not recruiting
  • Prostatic Neoplasms
  • Darolutamide (Nubeqa, BAY1841788)
  • +2 more
  • Macquarie University, New South Wales, Australia
  • +131 more
Jan 5, 2023

Prostate Cancer Trial (Darolutamide 300 mg, Placebo of Darolutamide)

Not yet recruiting
  • Prostate Cancer
  • Darolutamide 300 mg
  • Placebo of Darolutamide
  • (no location specified)
Feb 10, 2022

Polycystic Ovary Syndrome Trial (Ganirelix)

Not yet recruiting
  • Polycystic Ovary Syndrome
  • (no location specified)
Feb 20, 2023

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022

Prostatic Tumors Trial in Worldwide (Antiandrogen, Antiandrogen+docetaxel)

Active, not recruiting
  • Prostatic Neoplasms
  • Copenhagen, Denmark
  • +4 more
Aug 12, 2021

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023